Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus vector-based gene therapy designed to deliver a functional copy of the human coagulation factor IX (FIX) gene to the liver. It provides a one-time treatment to increase endogenous FIX activity levels, thereby reducing the frequency of bleeding episodes in patients with Hemophilia B.
## Primary Indications
Treatment of adults with moderately severe to severe Hemophilia B (congenital factor IX deficiency) who are currently using factor IX prophylactic therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is 5 x 10¹¹ vector genomes (vg) per kg of body weight, administered as a single intravenous infusion.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (under 18 years of age). Use in this population is currently not indicated.
## Dose Adjustments
No dose adjustments are permitted. The product is a one-time, fixed-dose infusion. There is no role for repeat administration due to the development of neutralizing antibodies against the AAV vector.
## Contraindications
* Known hypersensitivity to the active substance or any excipients.
* Active, uncontrolled infections (acute or chronic).
* Clinically significant hepatic impairment (due to the risk of reduced expression and increased hepatotoxicity).
## Adverse Effects
* **Most Common:** Elevation in liver enzymes (ALT/AST), infusion-related reactions (nausea, headache, tachycardia), and headache.
* **Serious:** Persistent elevation of liver enzymes leading to loss of therapeutic FIX expression, immune-mediated hepatotoxicity, and the potential for long-term integration-related malignancies (theoretical).
## Key Drug Interactions
* **Corticosteroids:** Highly likely to be required during the post-infusion period to manage immune-mediated hepatitis.
* **Hepatotoxic Agents:** Use with extreme caution as liver function must be closely monitored.
* **Factor IX Concentrates:** Should be tapered and eventually discontinued per clinical protocols as the patient’s endogenous FIX levels rise.
## Monitoring
* **Liver Function:** Alanine aminotransferase (ALT) must be monitored weekly for at least the first 3 months post-infusion to screen for immune-mediated responses.
* **Factor IX Activity:** Regularly monitor steady-state FIX activity levels post-infusion.
* **Bleeding Events:** Monitor for breakthrough bleeding despite treatment.
## Clinical Pearls
* **Pre-existing Immunity:** Patients with pre-existing neutralizing antibodies against AAVRh74 may not be eligible for therapy; screening is required before administration.
* **Prophylactic Steroids:** Patients are typically started on a prophylactic corticosteroid taper immediately following infusion to mitigate the risk of immune-mediated destruction of transduced hepatocytes, which would lead to loss of factor expression.
* **Longevity:** Long-term durability is still under evaluation; patients must remain in long-term follow-up registries.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult the latest FDA-approved prescribing information (package insert), your institution's clinical protocols, and manufacturer guidelines before prescribing or administering this gene therapy. Clinicians should be aware that gene therapies are subject to specialized institutional workflows and REMS (Risk Evaluation and Mitigation Strategy) requirements.
